BSX
Boston Scientific Corporation
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Strong growth and financial health scores — anchored by +19.9% revenue growth, +56.7% net income growth, a 0.46 debt-to-equity ratio, and 10.4x interest coverage — form the core of the composite score [growth.revenue.yoy, growth.net_income.yoy, financial_health.debt_to_equity, financial_health.interest_coverage].
- Solid but not exceptional profitability, with an 18.0% operating margin and a moderate 6.6% return on assets, contributed positively but tempered the overall result [profitability.operating_margin_pct, profitability.roa_pct].
- The Research Further label reflects a company with genuine fundamental strengths that nonetheless has unresolved questions around earnings consistency and unscored factors [momentum.net_income_quarterly, dividend.stale, theme.assigned].
Why Not Higher
- The dividend factor scored zero because no current dividend data passed the model's freshness threshold, and the Aging Population theme assignment did not translate into a positive score under the current methodology, together leaving meaningful potential score points uncaptured [dividend.stale, theme.assigned].
- Quarter-to-quarter volatility in operating and net income — with net income ranging from $670,000,000 to $1,339,000,000 across four quarters — prevented a higher momentum score despite stable revenue trends [momentum.net_income_quarterly, momentum.operating_income_quarterly].
Data Confidence
9 / 10
Very High — full data coverage
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew from $16,747,000,000 in FY2024 to $20,074,000,000 in FY2025, a gain of +19.9%, while net income rose +56.7% from $1,846,000,000 to $2,892,000,000 over the same period, and diluted EPS expanded +55.2% from $1.25 in FY2024 to $1.94 in FY2025.
The model rewarded the combination of double-digit top-line expansion and even faster bottom-line growth, which signals improving operating leverage and justifies a near-top score on this factor.
In FY2025, Boston Scientific posted an operating margin of 18.0%, a net margin of 14.4%, and a return on assets of 6.6%.
The margins indicate solid but not exceptional profitability relative to high-quality peers; the model appears to have rewarded the healthy operating and net margins while the moderate return on assets tempered the overall score.
In FY2025, the company carried a debt-to-equity ratio of 0.46 and an interest coverage ratio of 10.4, against a total asset base of $43,673,000,000.
A sub-1.0 debt-to-equity ratio and an interest coverage ratio well above 1.0 indicate that the company services its debt comfortably, which the model rewarded with a high score on this factor.
Quarterly revenue was broadly stable, ranging from $5,061,000,000 in 2025Q2 to $5,285,000,000 in 2025Q4 before easing to $5,203,000,000 in 2026Q1. Operating income showed more variability, moving from $819,000,000 in 2025Q2 up to $1,048,000,000 in 2025Q3, back to $825,000,000 in 2025Q4, and then rising again to $1,101,000,000 in 2026Q1. Net income was similarly uneven across the four quarters: $795,000,000, $755,000,000, $670,000,000, and $1,339,000,000 respectively.
The model appears to have credited the generally stable and growing revenue trend while the quarter-to-quarter oscillation in operating and net income introduced enough inconsistency to prevent a higher momentum score.
The company has an established history of paying dividends, though a current figure is not available within our filing-freshness window.
Because no fresh dividend data passed the model's recency threshold, the factor could not be scored positively, resulting in a score of zero regardless of the company's underlying dividend history.
Boston Scientific is assigned to the Aging Population macro theme.
Although the company is linked to the Aging Population theme — a category that reflects demographic tailwinds for medical device demand — this assignment did not translate into a positive score under the model's current methodology.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Boston Scientific delivered exceptional growth in FY2025, with revenue rising nearly 20% to $20,074,000,000 and net income surging 56.7% to $2,892,000,000, reflecting strong operating leverage [growth.revenue.yoy, growth.net_income.yoy]. Profitability metrics are solid, with an 18.0% operating margin and 14.4% net margin, though return on assets of 6.6% is moderate [profitability.operating_margin_pct, profitability.net_margin_pct, profitability.roa_pct]. The balance sheet is healthy, with a debt-to-equity ratio of 0.46 and interest coverage of 10.4x, providing meaningful financial flexibility [financial_health.debt_to_equity, financial_health.interest_coverage]. Quarterly momentum shows stable revenue but uneven operating and net income, and the absence of scoreable dividend or theme data limits the composite score to 56.3/100 with a Research Further label [momentum.revenue_quarterly, dividend.stale, theme.assigned].
Plain English
Boston Scientific is a medical device company that grew its sales by about 20% and nearly doubled its profit growth in the most recent full year, while keeping its debt low and manageable — but its quarterly earnings have been a bit up and down, and some scoring factors couldn't be measured, so it lands in 'Research Further' territory rather than a clear buy signal [growth.revenue.yoy, growth.net_income.yoy, financial_health.debt_to_equity, momentum.net_income_quarterly].
Bull Case vs. Bear Case
Bull Case
- Revenue grew +19.9% year-over-year to $20,074,000,000 in FY2025, while diluted EPS expanded +55.2% to $1.94, demonstrating powerful operating leverage that rewards shareholders disproportionately relative to top-line gains [growth.revenue.yoy, growth.eps_diluted.yoy].
- The balance sheet is conservatively structured with a debt-to-equity ratio of just 0.46 and an interest coverage ratio of 10.4x, meaning the company services its obligations comfortably and retains capacity for future investment [financial_health.debt_to_equity, financial_health.interest_coverage].
- Operating margins of 18.0% and net margins of 14.4% in FY2025 indicate a business generating meaningful profit on each dollar of revenue, supporting the durability of earnings growth [profitability.operating_margin_pct, profitability.net_margin_pct].
Bear Case
- Quarterly operating income oscillated significantly — from $819,000,000 in 2025Q2 to $1,048,000,000 in 2025Q3, back down to $825,000,000 in 2025Q4, and up again to $1,101,000,000 in 2026Q1 — raising questions about earnings consistency [momentum.operating_income_quarterly].
- Return on assets of 6.6% against a total asset base of $43,673,000,000 suggests the company is not yet generating exceptional returns on its large asset base, which may limit valuation upside [profitability.roa_pct, financial_health.total_assets].
- No current dividend data passed the model's recency threshold, meaning income-oriented investors cannot rely on a confirmed, up-to-date dividend yield from available filings [dividend.stale].
What Could Change the Picture
Bullish Triggers
- Consistent stabilization and growth in quarterly net income — which swung from $670,000,000 in 2025Q4 to $1,339,000,000 in 2026Q1 — if sustained, would signal that the earnings volatility is resolving in a positive direction [momentum.net_income_quarterly].
- A confirmed and growing dividend program, once fresh data becomes available, would add an income dimension to the already strong growth and financial health profile [dividend.stale].
Bearish Triggers
- A sustained deceleration in revenue growth from the current ~20% pace, or a compression of the 18.0% operating margin, would undermine the operating leverage thesis that drives the high growth score [growth.revenue.yoy, profitability.operating_margin_pct].
- A meaningful increase in the debt-to-equity ratio beyond the current 0.46, or a decline in interest coverage below comfortable levels, would erode the financial health advantage that currently supports the investment case [financial_health.debt_to_equity, financial_health.interest_coverage].
Risk Profile
Low RiskThe company's low debt-to-equity ratio of 0.46 and interest coverage of 10.4x indicate a low financial risk profile, supporting the Low risk rating [financial_health.debt_to_equity, financial_health.interest_coverage]. However, the quarter-to-quarter swings in operating and net income introduce some execution uncertainty that investors should monitor [momentum.operating_income_quarterly, momentum.net_income_quarterly].
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.